Agilent Technologies (A) Financials

Agilent Technologies’ latest quarter shows solid profitability and strong operating cash flow, but revenue growth remains modest and the company is still spending heavily on buybacks, dividends, and debt management. Over the past several years, Agilent has generally maintained healthy margins, consistent earnings, and reliable cash generation. However, the trend in recent quarters points to slower top-line growth, some pressure in operating cash flow from working capital, and a balance sheet that remains leveraged.

What stands out in Q1 2026 is that revenue slipped to $1.798 billion from $1.861 billion in Q4 2025 and was only slightly above the prior-year comparable quarter. Net income came in at $305 million, down from $434 million in the prior quarter and modestly below some of the stronger periods in 2024 and 2025. Even so, the company generated $268 million in operating cash flow, which is a positive sign for a business of this size.

Looking at the longer trend, Agilent has remained profitable through the cycle. Quarterly revenue has mostly ranged from about $1.57 billion to $1.86 billion over the last four years, while net income has typically stayed in the low-to-mid hundreds of millions per quarter. Gross margins and operating margins have generally been respectable, and the company has shown an ability to pass through at least some cost pressure. That said, the pace of growth has not been especially fast, and quarterly results have been choppy.

Cash flow remains a key strength. In Q1 2026, operating cash flow of $268 million easily covered capital spending of $93 million, leaving free cash flow that appears healthy even after dividends and repurchases. Across the recent history provided, Agilent has regularly produced positive operating cash flow, often well above $300 million per quarter in stronger periods. This supports ongoing capital returns to shareholders.

The balance sheet is manageable, but leverage is still meaningful. As of Q1 2026, Agilent had $1.76 billion in cash and equivalents against $3.05 billion in long-term debt and $304 million in short-term debt. Total liabilities were $5.91 billion versus $6.91 billion in common equity. That is not a distressed balance sheet, but it does leave the company with enough debt to watch if growth slows or margins compress.

• Consistent profitability: Agilent has stayed solidly profitable across the last four years, with net income regularly in the hundreds of millions per quarter.
• Healthy operating cash flow: Q1 2026 operating cash flow of $268 million shows the business still converts earnings into cash.
• Free cash flow generation: Capital spending remains manageable relative to operating cash flow, supporting shareholder returns.
• Strong liquidity: Cash and equivalents of $1.76 billion provide a sizeable cushion.
• Ongoing capital returns: The company continues to repurchase shares and pay dividends, signaling confidence in cash generation.
• Revenue growth is modest: Recent quarterly revenue has been mostly flat to slightly higher year over year, but not accelerating meaningfully.
• Margins remain respectable: Gross margin and operating income have generally held up, but there is no clear breakout in profitability.
• Working capital can be volatile: Q1 2026 saw a $155 million drag from changes in operating assets and liabilities, which can swing cash flow quarter to quarter.
• Balance sheet is stable but not ultra-conservative: Debt remains material, though not alarming relative to earnings power.
• Sequential earnings slowdown: Q1 2026 net income fell from the prior quarter’s $434 million to $305 million.
• Operating cash flow declined from Q4 2025: CFO fell to $268 million from $545 million, largely due to working capital pressure.
• Heavy buybacks and dividends consume cash: In Q1 2026, Agilent spent $152 million on repurchases and $72 million on dividends, which reduces flexibility.
• Meaningful debt load: Long-term debt of $3.05 billion limits financial flexibility compared with a net-cash balance sheet.

Bottom line: Agilent looks like a steady, cash-generative healthcare/life-science tools company rather than a rapid-growth story. The financials suggest resilience, but investors should expect moderate growth and watch for continued pressure from working capital, debt, and the size of capital returns relative to earnings.